Development trends for human monoclonal antibody therapeutics, Nat Rev Drug Discov, vol.9, pp.767-774, 2010. ,
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, vol.57, pp.4593-4599, 1997. ,
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, vol.3, pp.391-400, 2004. ,
Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, vol.364, pp.1897-1908, 2011. ,
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF, J Biol Chem, vol.281, pp.951-961, 2006. ,
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies, Proc Natl Acad Sci, vol.104, pp.3478-3483, 2007. ,
Interaction between bevacizumab and murine VEGF-A: a reassessment, Invest Ophthalmol Vis Sci, vol.49, pp.522-527, 2008. ,
,
, Br J Ophthalmol, vol.91, pp.804-807, 2007.
Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization, Mol Vis, vol.15, pp.2326-2338, 2009. ,
Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats, Ophthalmic Res, vol.42, pp.90-95, 2009. ,
Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model, Curr Eye Res, vol.35, pp.108-115, 2010. ,
Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival, Invest Ophthalmol Vis Sci, vol.51, pp.2411-2417, 2010. ,
Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model ,
, Acta Ophthalmol, vol.90, pp.564-570, 2012.
Avastin treatment reduces retinal neovascularization in a mouse model of retinopathy of prematurity, Curr Eye Res, vol.37, pp.624-629, 2012. ,
Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages, J Exp Med, vol.142, pp.1520-1533, 1975. ,
Fc receptors, Annu Rev Immunol, vol.9, pp.457-492, 1991. ,
URL : https://hal.archives-ouvertes.fr/hal-01996170
Divergent Immunoglobulin G subclass activity through selective Fc receptor binding, Science, vol.310, pp.1510-1512, 2005. ,
The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study, Korean J Ophthalmol, vol.27, pp.235-242, 2013. ,
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial, Lancet, vol.382, pp.1258-1267, 2013. ,
Angiogenesis in life, disease and medicine, Nature, vol.438, pp.932-936, 2005. ,
Drugs for macular degeneration, price discrimination, and Medicare's responsibility not to overpay, JAMA, vol.312, pp.23-24, 2014. ,
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth, Nat Med, vol.15, pp.1023-1030, 2009. ,
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth, Proc Natl Acad Sci, vol.106, pp.7137-7142, 2009. ,
Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity, Science, vol.346, pp.1000-1003, 2014. ,
Nucleoside reverse transcriptase inhibitors suppress laser-induced choroidal neovascularization in mice, Invest Ophthalmol Vis Sci, vol.56, pp.7122-7129, 2015. ,
IL-18 is not therapeutic for neovascular age-related macular degeneration, Nat Med, vol.20, pp.1372-1375, 2014. ,
Mouse model of angiogenesis, Am J Pathol, vol.152, pp.1667-1679, 1998. ,
Sequence-and target-independent angiogenesis suppression by siRNA via TLR3, Nature, vol.452, pp.591-597, 2008. ,
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinitymatured Fab in complex with antigen, J Mol Biol, vol.293, pp.865-881, 1999. ,
Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide, Nat Biotechnol, vol.18, pp.735-739, 2000. ,
Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, vol.355, pp.1432-1444, 2006. ,
Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, vol.355, pp.1419-1431, 2006. ,
Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase, Jpn J Ophthalmol, vol.52, pp.91-98, 2008. ,
Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo, Curr Eye Res, vol.33, pp.1002-1010, 2008. ,
CCR3 is a target for age-related macular degeneration diagnosis and therapy, Nature, vol.460, pp.225-230, 2009. ,
Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels, J Cell Physiol, vol.217, pp.13-22, 2008. ,
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A, J Clin Invest, vol.116, pp.422-429, 2006. ,
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region, J Immunol, vol.143, pp.2595-2601, 1989. ,
Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors, Biochem J, vol.259, pp.347-353, 1989. ,
Crosstalk between human IgG isotypes and murine effector cells, J Immunol, vol.189, pp.3430-3438, 2012. ,
Fc?RIV is a mouse IgE receptor that resembles macrophage Fc?RI in humans and promotes IgE-induced lung inflammation, J Clin Invest, vol.118, pp.3738-3750, 2008. ,
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor, J Pharmacol Exp Ther, vol.288, pp.371-378, 1999. ,
Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, pp.5640-5649, 2012. ,
Mouse model recapitulating human Fc? receptor structural and functional diversity, Proc Natl Acad Sci, vol.109, pp.6181-6186, 2012. ,
Specificity and affinity of human Fc? receptors and their polymorphic variants for human IgG subclasses, Blood, vol.113, pp.3716-3725, 2009. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00363931
Shifting Fc?RIIA-ITAM from activation to inhibitory configuration ameliorates arthritis, J Clin Invest, vol.124, pp.3945-3959, 2014. ,
IgG1 and IVIg induce inhibitory ITAM signaling through Fc?RIII controlling inflammatory responses, Blood, vol.119, pp.3084-3096, 2012. ,
Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fc?RI, in the presence of monomeric IgG, Blood, vol.116, pp.5327-5333, 2010. ,
Functional characteristics of the high affinity IgG receptor, Fc?RI, J Immunol, vol.186, pp.2699-2704, 2011. ,
Fc?RI-deficient mice show multiple alterations to inflammatory and immune responses, Immunity, vol.16, pp.379-389, 2002. ,
Fc?RI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection, Immunity, vol.16, pp.391-402, 2002. ,
The high-affinity IgG receptor, Fc?RI, plays a central role in antibody therapy of experimental melanoma, Cancer Res, vol.66, pp.1261-1264, 2006. ,
Antibody isotypespecific engagement of Fc? receptors regulates B lymphocyte depletion during CD20 immunotherapy, J Exp Med, vol.203, pp.743-753, 2006. ,
The importance of human Fc?RI in mediating protection to malaria, PLoS Pathog, vol.3, p.72, 2007. ,
Differential contribution of three activating IgG Fc receptors (Fc?RI, Fc?RIII, and Fc?RIV) to IgG2a-and IgG2b-induced autoimmune hemolytic anemia in mice, J Immunol, vol.180, pp.1948-1953, 2008. ,
The high-affinity human IgG receptor Fc?RI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy, Blood, vol.121, pp.1563-1573, 2013. ,
The function of Fc? receptors in dendritic cells and macrophages, Nat Rev Immunol, vol.14, pp.94-108, 2014. ,
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, J Clin Invest, vol.124, pp.812-823, 2014. ,
Mycobacterium tuberculosis inhibits IFN-? transcriptional responses without inhibiting activation of STAT1, J Immunol, vol.163, pp.3898-3906, 1999. ,
Mouse and human FcR effector functions, Immunol Rev, vol.268, pp.25-51, 2015. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01281740
The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes, Immunogenetics, vol.29, pp.92-97, 1989. ,
Further evidence that BALB/c and C57BL/6 ?2a genes originate from two distinct isotypes, EMBO J, vol.8, pp.3245-3251, 1989. ,
Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages, Nat Immunol, vol.13, pp.1118-1128, 2012. ,
Macrophage depletion inhibits experimental choroidal neovascularization, Invest Ophthalmol Vis Sci, vol.44, pp.3578-3585, 2003. ,
Differential binding to human Fc?RIIa and Fc?RIIb receptors by human IgG wildtype and mutant antibodies, Mol Immunol, vol.40, pp.585-593, 2003. ,
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc, J Immunol, vol.164, pp.4178-4184, 2000. ,
High resolution mapping of the binding site on human IgG1 for Fc?RI, Fc?RII, Fc?RIII, and FcRn and design of IgG1 variants with improved binding to the Fc?R, J Biol Chem, vol.276, pp.6591-6604, 2001. ,
Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions, J Immunol, vol.181, pp.4107-4112, 2008. ,
Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions, J Immunol, vol.181, pp.6664-6669, 2008. ,
Macrophage biology in development, homeostasis and disease, Nature, vol.496, pp.445-455, 2013. ,
IgG Fc receptors, Annu Rev Immunol, vol.19, pp.275-290, 2001. ,
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling, Cancer Res, vol.70, pp.3209-3217, 2010. ,
Differential interaction of Crkl with Cbl or C3G, Hef-1, and ? subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc?RI), J Immunol, vol.161, pp.5555-5563, 1998. ,
CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling, J Immunol, vol.160, pp.5018-5027, 1998. ,
Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes, Blood, vol.81, pp.2767-2773, 1993. ,
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, vol.87, pp.3336-3343, 1996. ,
The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis, J Biol Chem, vol.271, pp.17629-17634, 1996. ,
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice, Proc Natl Acad Sci, vol.95, pp.9349-9354, 1998. ,
The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1), FASEB J, vol.18, pp.929-931, 2004. ,
Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion, EMBO J, vol.24, pp.3807-3819, 2005. ,
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000. ,
Translating basic mechanisms of IgG effector activity into next generation cancer therapies, Cancer Immun, vol.12, p.13, 2012. ,
Macrophage regulation of tumor responses to anticancer therapies, Cancer Cell, vol.23, pp.277-286, 2013. ,
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc?RIII (CD16) deficient mice, Immunity, vol.5, pp.181-188, 1996. ,
Fc?RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo, Proc Natl Acad Sci, vol.107, pp.19396-19401, 2010. ,
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage, J Immunol, vol.184, pp.512-520, 2010. ,
The binding site for C1q on IgG, Nature, vol.332, pp.738-740, 1988. ,
Intravenous immune globulin suppresses angiogenesis in mice and humans, Signal Transduct Target Ther, vol.1, 2016. ,
Crystal structure of Fc? receptor I and its implication in high affinity ?-immunoglobulin binding, J Biol Chem, vol.286, pp.40608-40613, 2011. ,
Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with agerelated maculopathy, Arch Ophthalmol, vol.118, pp.625-629, 2000. ,
Unique monoclonal antibodies define expression of Fc?RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells, J Immunol, vol.170, pp.2549-2556, 2003. ,
A critical review of the role of Fc? receptor polymorphisms in the response to monoclonal antibodies in cancer, J Hematol Oncol, vol.6, 2013. ,
, Signal Transduction and Targeted Therapy website